MedDataX Logo

Zyvox (Linezolid) Special Investigation For Vancomycin-Resistant Enterococci (VRE)

NCT ID: NCT01224626

Last Updated: 2012-07-02

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

41 participants

Study Classification

OBSERVATIONAL

Study Start Date

2006-05-31

Study Completion Date

2011-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To collect the efficacy and safety information in subjects who have been treated with Zyvox (linezolid) for vancomycin resistance Enterococcus faecium infection for their appropriate use in daily practice.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Vancomycin Resistance Enterococcus Faecium

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

VRE Japanese Post Marketing Surveillance

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Zyvox (linezolid)

Patients who have been treated with Zyvox (linezolid).

Zyvox (linezolid)

Intervention Type DRUG

Patients should be treated with Zyvox (linezolid) 600 mg every twelve hours.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Zyvox (linezolid)

Patients should be treated with Zyvox (linezolid) 600 mg every twelve hours.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

linezolid, Zyvox

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subject to whom Zyvox (linezolid) was administered.
* Infected subject with Vancomycin resistance Enterococcus faecium.

Exclusion Criteria

* Infected subject with MRSA and other organism.
Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Pfizer

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Pfizer CT.gov Call Center

Role: STUDY_DIRECTOR

Pfizer

Related Links

Access external resources that provide additional context or updates about the study.

https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A5951139&StudyName=Zyvox%20%28Linezolid%29%20Special%20Investigation%20For%20Vancomycin-Resistant%20Enterococci%20%28VRE%29

To obtain contact information for a study center near you, click here.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

A5951139

Identifier Type: -

Identifier Source: org_study_id